International Association for the Study of Lung Cancer (IASLC) shared on LinkedIn:
“IASLC is proud to recognize Konstantinos Leventakos, recipient of an IASLC Career Advancement Grant.
His project, ‘Validating Ex Vivo Patient-Derived Microcancers as a Predictive Platform for Drug and Immunotherapy Response in Small Cell Lung Cancer,’ focuses on developing models that may help predict how patients respond to therapies.
Research like this has the potential to support more personalized treatment strategies and improve outcomes for people living with small cell lung cancer.
Congratulations, Konstantinos, on this exciting achievement!”
Other articles about International Association for the Study of Lung Cancer on OncoDaily.